Literature DB >> 1212798

In vitro transfer of tumour-specific immunity with human 'immune' RNA.

T Han, H Takita, P C Marabella, A Mittelman.   

Abstract

In vitro tumour-specific immunity against lung cancer was passively transferred in the leucocyte migration inhibition system with 'immune' RNA in man; 'non-immune' RNA, on the other hand, failed to transfer such immunity, indicating the specificity of 'immune' RNA.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1212798      PMCID: PMC1538085     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  7 in total

1.  Sedimentation characteristics of rapidly labelled RNA from HeLa cells.

Authors:  K SCHERRER; J E DARNELL
Journal:  Biochem Biophys Res Commun       Date:  1962-06-04       Impact factor: 3.575

2.  Proceedings: Transfer of cell-mediated skin reactivity with "immune" RNA in Hodgkin's disease and other neoplastic diseases.

Authors:  T Han
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

3.  'Immune' RNA-mediated transfer of delayed skin reactivity in patients with Hodgkin's disease.

Authors:  T Han
Journal:  Clin Exp Immunol       Date:  1973-06       Impact factor: 4.330

4.  Production of human chorionic gonadotropin in vitro by a cell line derived from a carcinoma of the lung.

Authors:  A S Rabson; S W Rosen; A H Tashijan; B D Weintraub
Journal:  J Natl Cancer Inst       Date:  1973-03       Impact factor: 13.506

5.  Transfer of tumor immunity with ribonucleic acid.

Authors:  Y H Pilch; K P Ramming
Journal:  Cancer       Date:  1970-09       Impact factor: 6.860

6.  Delayed hypersensitivity in man: a correlate in vitro and transfer by an RNA extract.

Authors:  D E Thor
Journal:  Science       Date:  1967-09-29       Impact factor: 47.728

7.  RNA-mediated transfer of tumor immunity--a new model for the immunotherapy of cancer.

Authors:  P J Deckers; Y H Pilch
Journal:  Cancer       Date:  1971-11       Impact factor: 6.860

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.